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The publication of the trial by Nanas et al. (1) in this issue
of the Journal, comparing two doses of enalapril in patients
with congestive heart failure (CHF), is timely. First, with
the results of the CONSENSUS (2), SOLVD (3,4) and
V-HeFT II (5) trials, we had a clear demonstration of the
benefits of angiotensin-converting enzyme (ACE) inhibi-
tors in patients with CHF. Then, there were the
NETWORK (6) and ATLAS (7) trials, testing whether a
“high” dose of ACE inhibitors did better than a low dose. In
fact, what was really compared was a standard dose and a
low dose. Now, there is a trial comparing a standard dose
and a really high dose of enalapril.
ACE INHIBITORS ARE EFFICACIOUS IN PATIENTS
WITH CHF (DUE TO SYSTOLIC DYSFUNCTION)
Thirteen years ago, a major advance occurred in the treat-
ment of CHF with the publication of the CONSENSUS
trial results (2). Enalapril was tested in New York Heart
Association (NYHA) class IV patients. The trial was
stopped much earlier than scheduled (inclusion of 253
patients, 400 planned) because of the major difference in
mortality between the two groups: at six months the
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mortality rate was as high as 44% in the placebo group; it
was 26% in the enalapril group (reduction in relative risk,
40%). There was also a nice functional improvement. The
planned dose in the enalapril group was 40 mg/d (20 mg
twice daily). However, only 28% of the patients tolerated
this dosage; the mean dose was 18 mg/d.
The population that could benefit from ACE inhibitors
was broadened when the SOLVD trials results were pub-
lished. In the so-called “SOLVD-treatment trial,” in pa-
tients with left ventricular ejection fraction (LVEF) #35%,
patients had to be in NYHA class II to IV (3). They were
mainly in class II or III (class I—not to be included, 10.5%;
class IV, only 1.9%). After a mean follow-up of 41 months,
the mortality rate was 39.7% in the placebo group and
35.2% in the enalapril group (reduction in relative risk:
16%). The target dose of enalapril was 20 mg/d (10 mg
twice daily), but only half of the patients received it, and the
mean dose received by the patients actually taking the drug
was 17 mg/d.
In the “SOLVD-prevention trial,” also in patients with
LVEF #35%, the patients had to be asymptomatic (how-
ever, 33% were in NYHA class II) (4). There was no
significant effect of enalapril on mortality, but fewer
enalapril-treated patients developed CHF: 20.7% vs. 30.2%,
after a mean follow-up of 37 months. As in the previous
trial, the target dose was 20 mg/d, but only half of the
patients received it, and the mean dose received by the
patients actually taking the drug was 17 mg/d.
The V-HeFT II trial was not placebo-controlled (5). It
compared enalapril with hydralazine-isosorbide dinitrate,
which had been proven superior to placebo in a previous
V-HeFT trial (8). In V-HeFT II, patients were mainly in
NYHA class II (51%) or III (43%). At two years, mortality
was 25% in the hydralazine-isosorbide dinitrate group and
18% in the enalapril group (reduction in relative risk, 28%).
Overall (including patients who stopped taking the drug),
the average daily dose of enalapril was 15 mg.
We therefore had clear evidence of the beneficial effects
of enalapril on mortality, hospitalizations and functional
class in patients with CHF. The next question was: what is
the optimal dose (9,10)? Very often patients do not receive
the target dose proven efficacious in the clinical trials, and in
those receiving ACE inhibitors, the dosage is much lower
than the dose tested in the clinical trials (11–14).
ARE THE STANDARD DOSES
MORE EFFICACIOUS THAN LOW DOSES?
The NETWORK (6) and ATLAS (7) trials, published in
1998 and 1999, respectively, intended to investigate the
dose-response relationship of ACE inhibitors in patients
with CHF. In NETWORK, 1,532 patients were random-
ized to receive enalapril 5, 10 or 20 mg/d (drug given twice
daily) (6). Two thirds of the patients were in NYHA class
II, the other third was class III or IV. All patients took the
prescribed dose in the low dose group: 96% did so in the
medium dose group, and 85% did so in the “high” dose
group. After a follow-up of 5.5 months, the rate of wors-
ening of heart failure was exactly the same in the three
groups (7.8%). Heart failure–related hospitalizations were
not less frequent in higher dose groups (low dose, 5.1%;
medium dose, 5.5%; high dose, 7.0%). There was a trend
toward a lower death rate with increasing dose, 4.2%, 3.3%
and 2.9%, respectively, but this was not significant. The
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changes in functional class were similar in the three groups.
Treatment withdrawals were more frequent in the 20-mg/d
group (27%) than in the two other groups (19% each). Thus,
do these results imply that 5 mg of enalapril per day is
sufficient (as efficacious on hard end points as higher doses
and better tolerated)?
This may be so, but the ATLAS trial results suggest that
high doses bring more benefit than lower doses (7). The
3,164 patients were randomized to receive 2.5 to 5.0 mg or
32.5 to 35 mg of lisinopril per day. They all had a LVEF
#30%. The NYHA class was mainly III (77%, II: 16%, IV:
7%). After a median follow-up of 46 months, the mortality
rate was 44.9% in the low dose group and 42.5% in the high
dose group, a nonsignificant difference. However, the num-
ber of hospitalizations was lower in the high dose group—
3,819 vs. 4,397 (p 5 0.02); the difference was larger for
hospitalizations for heart failure—1,199 vs. 1,576 (p 5
0.002). There was no difference in the evolution of the
NYHA class between the two groups.
What is called “high” doses should more adequately be
called “standard” doses. The authors say that “doses of 20 to
40 mg (of lisinopril) daily were comparable to the doses of
ACE inhibitors used in clinical trials that demonstrated a
reduction in morbidity and mortality.” The references are
the CONSENSUS trial (2), the SOLVD trial (3) and
another trial (15); but these trials did not compare the effect
of different ACE inhibitors on mortality, and we thus do
not know the comparable doses of different ACE inhibitors.
All together, standard doses look superior to lower doses.
However, we still did not know whether standard doses
were the optimal ones. This is why the present trial (1) is
timely.
ARE HIGH DOSES MORE
EFFICACIOUS THAN STANDARD DOSES?
In this randomized trial, 248 patients received either 10 mg
or 30 mg of enalapril twice daily. Left ventricular ejection
fraction had to be #35%; the mean was 19%. The NYHA
class was II in 42% of the patients, III in 44% and IV in the
remaining. This population resembles that of the SOLVD
treatment trial (3). The mean daily dose of enalapril was
18 mg in the 20-mg dose group and 42 mg in the 60-mg
dose group. At one year, the target dose was achieved in
80% of the 20-mg dose patients but in only 45% of the
60-mg dose patients. Nevertheless, even if the target doses
were not often achieved, this trial did compare standard
doses (the ones achieved in the CONSENSUS, SOLVD
and V-HeFT II trials) and high doses.
The mortality rate was exactly the same in both groups:
18% at one year. There was no difference in survival between
the two groups in subgroup analyses according to age,
etiology of heart failure, blood pressure, heart rate or
ejection fraction. Similarly, there was no difference in terms
of hospitalizations, of ejection fraction changes (nice im-
provement, from 20% to 30% in both groups) and func-
tional status changes (from NYHA class 2.6 to 1.9 in both
groups).
All trials put together, the conclusion is that doses of
enalapril .20 mg/d are not more efficacious than standard
doses, but that we should always try to reach a dose of
20 mg/d (10 mg twice daily) of enalapril in patients with
CHF due to systolic dysfunction.
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